At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 681 enrolled
Drug / intervention
GWP42003-Pdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open Label Extension Study to Investigate the Safety of Cannabidiol (GWP42003-P; CBD) in Children and Adults With Inadequately Controlled Dravet or Lennox-Gastaut Syndromes.
In Brief
A Phase 3 clinical trial evaluating GWP42003-P for Epilepsy and 2 related conditions. Completed, enrolled 681 participants.
Detailed Summary
To investigate the potential antiepileptic effects of cannabidiol (GWP42003-P) in children and adults with Dravet or Lennox-Gastaut syndromes.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEpilepsy, Dravet Syndrome, Lennox-Gastaut Syndrome
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
First PostedAug 2014
Enrollment StartJun 2015
Primary CompletionSep 2020
TodayJul 2026
First PostedAug 25, 2014
Enrollment StartJun 11, 2015
Primary CompletionSep 24, 2020
TodayJul 2, 2026
Enrollment to primary: 5.3 yearsPosted 11.9 years ago
Interventions
GWP42003-Pdrug